Zupan, Irena Preloznik
Rener, Karla
Doma, Sasa Anzej
Funding for this research was provided by:
Novo Nordisk
AdriaSonara d.o.o.
Article History
Accepted: 6 November 2022
First Online: 8 December 2022
Declarations
:
: The market research survey was developed by AdriaSonara d.o.o. and funded by Novo Nordisk. Open Access funding enabled and organized by Novo Nordisk.
: IPZ received honoraria and speaker fees from Bayer Health Care, Novo Nordisk, Octapharma, Pfizer, Roche, SOBI and Takeda, has been a speaker at satellite symposia during scientific meetings for Novo Nordisk and Roche. SAD received honoraria and speaker fees from Bayer, Novo Nordisk, Pfizer, Roche and SOBI, and reimbursements for attending congresses from Bayer, Octapharma, Pfizer and Roche. KR received honoraria and speaker fees from Novo Nordisk, Roche, and Takeda, and has been a speaker at satellite symposia during scientific meetings for Novo Nordisk and Roche.
: The data that support the findings of this study are available from the corresponding author upon reasonable request.
: This study was exempt from requiring ethics approval in line with national guidelines (Ministry of Health, Commission for Medical Ethics).
: All patients who were registered in one or both of two national patient organizations, or their caregivers, were invited to participate in the survey if they had provided informed consent for their information to be used for such purposes.
: Patients provided informed consent regarding publishing their data.
: IPZ, KR and SAD were involved in the conduct of the study and in the interpretation of study results. All authors directed the data analysis and the development of the manuscript, and approved the final version of the manuscript.